Hypermethylation of p16 and p53 promoter regions occurred in 35.0% and 36.5% of healthy controls, 46.0% and 42.0% of EPL cases, and 63.0% and 56.5% of ESCC cases, respectively. The gene discussed is CDKN2A; the disease is esophageal squamous cell carcinoma.